189 related articles for article (PubMed ID: 32566462)
1. Peripheral Artery Disease and Stroke.
Zito C; Manganaro R; Carerj S; Antonini-Canterin F; Benedetto F
J Cardiovasc Echogr; 2020 Apr; 30(Suppl 1):S17-S25. PubMed ID: 32566462
[TBL] [Abstract][Full Text] [Related]
2. The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study.
Haguet H; Bouvy C; Delvigne AS; Modaffari E; Wannez A; Sonveaux P; Dogné JM; Douxfils J
Front Pharmacol; 2020; 11():1007. PubMed ID: 32719607
[TBL] [Abstract][Full Text] [Related]
3. Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors.
Kondapalli L; Worth S; Hawi R; Vachhani P; Arora G; Bhatia R; Lenneman CG
Vasc Med; 2020 Jun; 25(3):246-254. PubMed ID: 32303152
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.
Damrongwatanasuk R; Fradley MG
Curr Treat Options Cardiovasc Med; 2017 Apr; 19(4):24. PubMed ID: 28316033
[TBL] [Abstract][Full Text] [Related]
5. Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response.
Hamadi A; Grigg AP; Dobie G; Burbury KL; Schwarer AP; Kwa FA; Jackson DE
Thromb Haemost; 2019 Jul; 119(7):1112-1123. PubMed ID: 31079415
[TBL] [Abstract][Full Text] [Related]
6. The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model.
Pouwer MG; Pieterman EJ; Verschuren L; Caspers MPM; Kluft C; Garcia RA; Aman J; Jukema JW; Princen HMG
Front Cardiovasc Med; 2018; 5():55. PubMed ID: 29946549
[TBL] [Abstract][Full Text] [Related]
7. Current perspectives for the treatment of chronic myeloid leukemia.
Aladağ E; Haznedaroğlu İC
Turk J Med Sci; 2019 Feb; 49(1):1-10. PubMed ID: 30761815
[TBL] [Abstract][Full Text] [Related]
8. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
10. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
11. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
12. Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data.
Lang K; McGarry LJ; Huang H; Dorer D; Kaufman E; Knopf K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):275-285.e1. PubMed ID: 27013180
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing.
Medeiros BC; Possick J; Fradley M
Blood Rev; 2018 Jul; 32(4):289-299. PubMed ID: 29454474
[TBL] [Abstract][Full Text] [Related]
14. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
Wong SF; Mirshahidi H
Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
[TBL] [Abstract][Full Text] [Related]
15. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis.
Chai-Adisaksopha C; Lam W; Hillis C
Leuk Lymphoma; 2016; 57(6):1300-10. PubMed ID: 26373533
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention.
Lee DH; Fradley MG
Curr Treat Options Cardiovasc Med; 2018 Mar; 20(3):19. PubMed ID: 29508087
[TBL] [Abstract][Full Text] [Related]
17. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
[TBL] [Abstract][Full Text] [Related]
19. Ponatinib: A Third-Generation Inhibitor for the Treatment of CML.
Wehrle J; von Bubnoff N
Recent Results Cancer Res; 2018; 212():109-118. PubMed ID: 30069627
[TBL] [Abstract][Full Text] [Related]
20. [State-of-the-art management of CML in 2015 and future prospects].
Kimura S
Rinsho Ketsueki; 2015 Oct; 56(10):2005-14. PubMed ID: 26458439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
